-
Something wrong with this record ?
Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder
M. Rejchrt, J. Krhut, M. Gärtner, BFM. Blok, P. Zvara
Language English Country Germany
Document type Journal Article
NLK
ProQuest Central
from 1997-02-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2000-02-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-02-01 to 1 year ago
- MeSH
- Electric Stimulation Therapy * MeSH
- Urinary Bladder, Overactive * therapy MeSH
- Humans MeSH
- Follow-Up Studies MeSH
- Prospective Studies MeSH
- Transcutaneous Electric Nerve Stimulation * MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
PURPOSE: The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) in patients with overactive bladder (OAB). METHODS: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM®. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient's request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM®. The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM®. Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation. RESULTS: The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM® was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017). CONCLUSION: The treatment effect achieved during the initial phase of peroneal eTNM® persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.
Department of Surgical Studies Faculty of Medicine Ostrava University Ostrava Czech Republic
Department of Urology Erasmus Medical Center Rotterdam The Netherlands
Department of Urology Odense University Hospital Odense Denmark
Department of Urology University Hospital Ostrava Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011221
- 003
- CZ-PrNML
- 005
- 20230801132902.0
- 007
- ta
- 008
- 230718s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-023-04394-z $2 doi
- 035 __
- $a (PubMed)37027023
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Rejchrt, Michal $u Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic $u Urological Office, Poliklinika RAVAK, Příbram, Czech Republic
- 245 10
- $a Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder / $c M. Rejchrt, J. Krhut, M. Gärtner, BFM. Blok, P. Zvara
- 520 9_
- $a PURPOSE: The aim of this prospective 12-month follow-up study is to evaluate the persistence of the treatment effect achieved during the initial course of peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) in patients with overactive bladder (OAB). METHODS: This study enrolled 21 female patients who participated in two previous clinical studies designed to assess the efficacy and safety of peroneal eTNM®. The patients were left without subsequent OAB treatment and were invited to attend regular follow-up visits every 3 months. The patient's request for additional treatment was considered an indicator of the withdrawal of the treatment effect of the initial course of peroneal eTNM®. The primary objective was the proportion of patients with persisting treatment effect at follow-up visit 12 months after initial course of peroneal eTNM®. Descriptive statistics are presented using median, correlation analyses were computed using a nonparametric Spearman correlation. RESULTS: The proportion of patients with persistent therapeutic effect of the initial course of peroneal eTNM® was 76%, 76%, 62% and 48% at 3, 6, 9 and 12 months, respectively. There was a significant correlation between patient reported outcomes and the number of severe urgency episodes with or without urgency incontinence as reported by patients at each follow-up visit (p = 0.0017). CONCLUSION: The treatment effect achieved during the initial phase of peroneal eTNM® persists for at least 12 months in 48% of patients. It is likely that the duration of effects is dependent on the length of the initial therapy.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a hyperaktivní močový měchýř $x terapie $7 D053201
- 650 12
- $a transkutánní elektrická neurostimulace $7 D004561
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a prospektivní studie $7 D011446
- 650 12
- $a elektrostimulační terapie $7 D004599
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Krhut, Jan $u Department of Urology, University Hospital, Ostrava, Czech Republic. jan.krhut@fno.cz $u Department of Surgical Studies, Faculty of Medicine, Ostrava University, Ostrava, Czech Republic. jan.krhut@fno.cz $1 https://orcid.org/0000000342055926 $7 mzk2005309234
- 700 1_
- $a Gärtner, Marcel $u Gynuro s.r.o., Ostrava, Czech Republic
- 700 1_
- $a Blok, Bertil F M $u Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
- 700 1_
- $a Zvara, Peter $u Biomedical Laboratory and Research Unit of Urology, Department of Clinical Research, University of Southern Denmark, Odense, Denmark $u Department of Urology, Odense University Hospital, Odense, Denmark
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 41, č. 6 (2023), s. 1629-1634
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37027023 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132858 $b ABA008
- 999 __
- $a ok $b bmc $g 1963548 $s 1197486
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 41 $c 6 $d 1629-1634 $e 20230407 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20230718
